The North America Smart Insulin Pen Market would witness market growth of 9.3% CAGR during the forecast period (2018 – 2024).
Insulin pens have gained popularity in the recent years. Consequently, smart insulin pens are gaining prominence in their adoption for supplying insulin externally, and as a result, they offer better diabetes management system. The demand is due to rapidly rising number of diabetic patients, and cost-effectiveness of the smart insulin pens. Another benefit of the devices is, it allows dialing the dose accurately, and serving people with vision problems administer insulin easily further contributed to the market growth. In addition, the simple functioning and accurate delivery of appropriate dosing adds to the demand. Nevertheless, some limitations prevail that limit the market growth, such as such as two types of insulin cannot be mixed in an insulin pen, therefore, leading more number of injections. Smart insulin pens are best in many ways as compared to other insulin delivery devices. These pens are easier to use than syringe and are portable, which makes them easy to be used anywhere.

Based on Product, the market is segmented into Second Generation Pens and First Generation Pens. Based on Usability, the market is segmented into Prefilled and Reusable. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgical Centers and Home care settings. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Companion Medical Inc., Digital Medics Ptd Ltd., Eli Lilly and Company, Novo Nordisk A/S, Diamesco Co., Ltd., F. Hoffmann-La Roche AG, Insulet Corporation, Emperra GmbH E-Health Technologies, Jiangsu Delfu medical device Co. Ltd., Bigfoot biomedica.